km-2210 and Carcinosarcoma

km-2210 has been researched along with Carcinosarcoma* in 1 studies

Other Studies

1 other study(ies) available for km-2210 and Carcinosarcoma

Article	Year
Effects of intraarterial chemotherapy using the new lipophilic anticancer agent 'KM2210' (estradiol-chlorambucil) dissolved in lipiodol on Walker 256 carcinosarcoma in Wistar rats--a preliminary report. European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 1990, Volume: 22, Issue:4 The effect of a new oil-soluble anticancer agent 'KM2210' (estradiol-chlorambucil) dissolved in lipiodol (LPD) was investigated as intraarterial chemotherapy, using 40 Wistar rats bearing Walker 256 carcinosarcoma in the extremities. KM2210-LPD significantly inhibited tumor growth and prolonged the survival time, as compared to LPD alone or saline alone, p less than 0.01 and p less than 0.01, respectively. Pathological study revealed that KM2210-LPD made the tumor necrotic. It was revealed that KM2210-LPD injected into the femoral artery was retained in the hind limb tumor. These findings suggest that KM2210 may possibly become a new anticancer agent with potential clinical use in LPD chemoembolization. Topics: Animals; Antineoplastic Agents; Carcinosarcoma; Chlorambucil; Dose-Response Relationship, Drug; Estradiol; Extremities; Female; Infusions, Intra-Arterial; Iodized Oil; Necrosis; Neoplasm Transplantation; Rats; Rats, Inbred Strains; Solutions	1990

Article

Year

Effects of intraarterial chemotherapy using the new lipophilic anticancer agent 'KM2210' (estradiol-chlorambucil) dissolved in lipiodol on Walker 256 carcinosarcoma in Wistar rats--a preliminary report.

European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 1990, Volume: 22, Issue:4

The effect of a new oil-soluble anticancer agent 'KM2210' (estradiol-chlorambucil) dissolved in lipiodol (LPD) was investigated as intraarterial chemotherapy, using 40 Wistar rats bearing Walker 256 carcinosarcoma in the extremities. KM2210-LPD significantly inhibited tumor growth and prolonged the survival time, as compared to LPD alone or saline alone, p less than 0.01 and p less than 0.01, respectively. Pathological study revealed that KM2210-LPD made the tumor necrotic. It was revealed that KM2210-LPD injected into the femoral artery was retained in the hind limb tumor. These findings suggest that KM2210 may possibly become a new anticancer agent with potential clinical use in LPD chemoembolization.

Topics: Animals; Antineoplastic Agents; Carcinosarcoma; Chlorambucil; Dose-Response Relationship, Drug; Estradiol; Extremities; Female; Infusions, Intra-Arterial; Iodized Oil; Necrosis; Neoplasm Transplantation; Rats; Rats, Inbred Strains; Solutions

1990